Lukang Pharmaceutical announced on August 7 that its holding subsidiary Saite received the “Drug Supplement Application Approval Notice” for amikacin sulfate injections issued by the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.